Phase II evaluation of fluorouracil and recombinant α-2a-interferon in previously untreated patients with pancreatic adenocarcinoma

This publication has 12 references indexed in Scilit:

• Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.
  Journal of Clinical Oncology, 1990
• Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group.
  Journal of Clinical Oncology, 1986
• Chemotherapy for advanced pancreatic cancer.A comparison of 5-fluorouracil, adriamycin, and mitomycin (fam) with 5-fluorouracil, streptozotocin, and mitomycin (fsm)
  Cancer, 1986
• A Comparison of Three Chemotherapeutic Regimens in the Treatment of Advanced Pancreatic and Gastric Carcinoma
  JAMA, 1985
• Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest oncology group study
  Cancer, 1983
• Recombinant Leukocyte A Interferon: Pharmacokinetics, Single-Dose Tolerance, and Biologic Effects in Cancer Patients
  Annals of Internal Medicine, 1982
• 5 FU infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer. A Southwest oncology group study
  Cancer, 1979
• Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer
  Cancer, 1978
• Chemotherapy of Gastrointestinal Cancer
  Clinics in Gastroenterology, 1976
• A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer
  Cancer, 1974